17:01 , Jan 11, 2019 |  BC Week In Review  |  Company News

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular...
20:51 , Jan 4, 2019 |  BC Extra  |  Company News

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular...
20:46 , Dec 21, 2018 |  BC Week In Review  |  Company News

FDA picks Flatiron's Abernethy for No. 2 spot

FDA has hired data scientist and oncologist Amy Abernethy of Flatiron Health Inc. for its No. 2 spot, succeeding Rachel Sherman, who is retiring. FDA Commissioner Scott Gottlieb told BioCentury he expects Abernethy to evaluate...
15:21 , Dec 17, 2018 |  BC Extra  |  Politics & Policy

FDA picks Flatiron’s Abernethy for No. 2 spot

FDA has hired data scientist and oncologist Amy Abernethy of Flatiron Health Inc. for its No. 2 spot, succeeding Rachel Sherman, who is retiring. FDA Commissioner Scott Gottlieb told BioCentury he expects Abernethy to evaluate...
22:10 , Oct 15, 2018 |  BC Extra  |  Politics & Policy

FDA guides on minimal residual disease endpoint in hematologic cancer trials

FDA Commissioner Scott Gottlieb highlighted minimal residual disease (MRD)'s potential as a surrogate endpoint in clinical trials when he unveiled FDA's draft guidance on using MRD in hematologic malignancy drug development in a statement Monday....
19:29 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves minimal residual disease diagnostic

FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay is the first...
22:39 , Sep 28, 2018 |  BC Extra  |  Company News

FDA approves minimal residual disease diagnostic

FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay is the first...
18:15 , Sep 7, 2018 |  BC Week In Review  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at...
20:15 , Sep 6, 2018 |  BC Extra  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at...
22:48 , Jan 5, 2018 |  BC Week In Review  |  Company News

Adaptive, Microsoft to develop universal TCR-antigen map

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Microsoft Corp.(NASDAQ:MSFT) partnered to develop a universal map of T cell receptors (TCRs) and their antigens using Adaptive's immunosequencing platform and Microsoft's research, machine-learning and cloud computing technologies. The...